Drug for Rare Genetic Disease Gets FDA Approval

Angiodema Drug Approved By FDA
HealthDay News


THURSDAY, July 17, 2014 (HealthDay News) -- Ruconest has been approved by the U.S. Food and Drug Administration to treat hereditary angioedema, a genetic disease that leads to sudden and potentially fatal swelling of the hands, feet, limbs, face, intestinal tract or airways.

The disease, affecting as many as 10,000 people in the United States, is caused by the body's inability to produce enough of a plasma protein called C1-esterase inhibitor. The remedy is produced from the milk of genetically-modified rabbits, the FDA said Thursday in a news release.

Ruconest was evaluated in a clinical study of 44 adults and adolescents with hereditary angioedema. The most common side effects recorded were headache, nausea and diarrhea.

Ruconest is manufactured by the Netherlands-based Pharming Group NV, and will be distributed by a subsidiary of Salix Pharmaceuticals, based in Raleigh, NC.

Copyright © 2014 HealthDay. All rights reserved.

Published: July 2014

ADVERTISEMENT

15 Minutes With Dr. Lauren Gardner

You may not know her name, but you've probably used the dashboard she and her team created to track Covid-19

Your Health

Nearly 60 Million Americans Don’t Drink Their Tap Water, Research Suggests – Here’s Why That’s a Public Health Problem

People who don't trust their tap water shift to more expensive and often less healthy options, like bottled water or sugary drinks

Your Wellness

Johnson & Johnson Vaccine Suspension – What This Means for You

The pause is due to reports of blood clotting in six people (out of 6.8 million doses) who have received the vaccine.

Prevention & Screenings